| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2018: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
Leukemias carrying mutations of the MLL gene are frequently found in infants and often associated with poor prognosis. We investigated the molecular mechanisms of MLL-associated leukemia and proposed a novel therapeutic approach based on our findings.
MLL is a protein responsible for gene regulation. We found that MLL mutant proteins function as a hyper-active gene regulator dependently on two proteins, namely, AF4 and DOT1L. We showed experimentally that simultaneous inhibition of these two proteins by molecularly-targeted drugs exerted strong anti-tumor effects in mouse disease models.
|
